Clinical trial · Observational
Exploring the Evolution of Quality of Life and Emotional Distress Among Cancer Patients Participating in Mind-body Therapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer incidence is increasing worldwide, and although survival rates have improved thanks to advances in treatment and early detection, many patients continue to experience reduced quality of life (QoL), anxiety, depression, and distress. Mind-body therapies (MBTs)-including mindfulness, laughter yoga, and art therapy-are increasingly integrated into supportive oncology care. Evidence suggests these therapies may improve psychosocial well-being; however, existing research often suffers from methodological limitations, small samples, and limited generalizability. The OTIUM centers in Geneva and Meyrin offer structured MBT programs to cancer patients. This project aims to evaluate the evolution of QoL and emotional distress in patients participating in one of these therapies, using validated patient-reported outcome measures (PROMs).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Mind-Body Therapies | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- OTIUM Minb-body therapy cohort
- description
- This cohort includes adult cancer patients participating in one specific mind-body therapy (MBT) offered at the OTIUM Centers in Geneva and Meyrin. Eligible participants take part in a structured program-mindfulness, laughter yoga, or art therapy-delivered in a group format over approximately 8 to 10 weeks. The cohort is designed to evaluate changes in quality of life and emotional distress associated with participation in the selected MBT. All participants complete standardized patient-reported outcome measures (EORTC QLQ-C30 and HADS) before and after the therapy.
Primary outcomes (1)
- measure
- Quality of life
- timeFrame
- From enrollment to the end of treatment at (approximately) 8 weeks
- description
- The primary variable of interest is the total score on the EORTC QLQ-C30, measured at baseline and at the end of treatment, on average 8 weeks after start of treatment. The EORTC QLQ-C30 is scored on a 0 to 100 scale, with higher scores indicating better quality of life for the global health status/quality of life scale. This outcome was selected because it is the most widely used PROM, which facilitates interpretation and comparison with existing literature, and enables us to better assess the quality of care we provide.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient diagnosed with cancer * Acceptance and signature of an informed consent form * Age of majority * Completion of one of the therapies concerned. Exclusion Criteria: * Withdrawal of the signed informed consent form * Metastatic cancer * Cancer recurrence * Drugs use against stress * Memory disorders * History or current use of a MBT
References
Publications (0)
Data not yet available